You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Nefazodone hydrochloride
Nefazodone hydrochloride is a serotonin 5-HT2A receptor antagonist (Ki = 5.8 nM) and inhibitor of serotonin and noradrenalin uptake (IC50 values are 290 and 300 nM respectively). Displays no activity at 5-HT1B and 5-HT1D receptors. Active in models predictive of antidepressant potential.
Technical Data for Nefazodone hydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Nefazodone hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Nefazodone hydrochloride
The following data is based on the product molecular weight 506.47. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||7.9 mL||39.49 mL||78.98 mL|
|1.25 mM||1.58 mL||7.9 mL||15.8 mL|
|2.5 mM||0.79 mL||3.95 mL||7.9 mL|
|12.5 mM||0.16 mL||0.79 mL||1.58 mL|
Product Datasheets for Nefazodone hydrochloride
References for Nefazodone hydrochloride
References are publications that support the biological activity of the product.
Eison et al (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol.Bull. 26 311 PMID: 2274630
Davis et al (1997) Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53 608 PMID: 9098663
Pullar et al (2000) LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine2A receptor antagonist: a comparison with the antidepressant, nefaz. Eur.J.Pharmacol. 407 39 PMID: 11050288
If you know of a relevant reference for Nefazodone hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Nefazodone hydrochloride, Nefazodone hydrochloride supplier, 5-HT2A, antagonists, reuptake, inhibitors, inhibits, Antidepressant, Serotonin, Receptors, Transporters, SERT, 5-Hydroxytryptamine, Monoamine, Neurotransmitter, 5-HT, 2777, Tocris Bioscience
Citations for Nefazodone hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Nefazodone hydrochloride. Do you know of a great paper that uses Nefazodone hydrochloride from Tocris? Please let us know.
Reviews for Nefazodone hydrochloride
There are currently no reviews for this product. Be the first to review Nefazodone hydrochloride and earn rewards!
Have you used Nefazodone hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.